- Email: [email protected]
Melanoma vaccines
202
We analysed metastasis and clonal evolution of a mouse fibrosarcoma line, 505-05-01 cells, by genetic tagging of these ceils. This line was transfected with pSV2neo plasmid and 22 clones were randomly isolated. These clones were readily distinguishable by the pattern of integration of the plasmid. Mixture of the clones were transplanted
in syngenic mice and the resulting tumors and metastatic nodules were analysed by Southern blotting. The analysis revealed that a dominant clone took over the tumor and it also metasatsized in lung. Nature of clonal evolution in an experimental system will be discussed.
3.
Melanoma vaccines Kazuhito
Hayashibe,
Yutaka Mishima
and Soldano
Ferrone
Department of Dermatology, Kobe University School of Medicine, Kobe
A large number of patients have been injected with various tumor vaccines including novel immunological adjuvants, anti-idiotype MoAbs and carbohydrate antigens over the recent fifty years. However all of them have been of limited success to obtain substantial responses against melanoma except a few occasional cases. To develop new reagents with a firmer immunological basis, our approach is to screen an expression cDNA library constructed with a cultured human melanoma cell line mRNA utilizing sera from patients with melanoma. A cloned cDNA (1029 bps), designated as D-l, encodes a polypeptide with the apparent molecular weight of
40 kd. The size of the melanoma-associated antigen polypeptide D- 1 is different from that of previously described melanoma-associated antigens defined with antibodies from patients with melanoma and with mouse MoAbs. The nucleic acid sequence of cDNA D-l has no striking homology with previously reported sequences of mammalian genes. In situ hybridization on surgically removed melanoma tissues has indicated that this antigen is expressed in vivo. Thus D-l melanoma-associated antigen may be a useful immunogen to implement active specific immunotherapy in patients with melanoma.
We analysed metastasis and clonal evolution of a mouse fibrosarcoma line, 505-05-01 cells, by genetic tagging of these ceils. This line was transfected with pSV2neo plasmid and 22 clones were randomly isolated. These clones were readily distinguishable by the pattern of integration of the plasmid. Mixture of the clones were transplanted
in syngenic mice and the resulting tumors and metastatic nodules were analysed by Southern blotting. The analysis revealed that a dominant clone took over the tumor and it also metasatsized in lung. Nature of clonal evolution in an experimental system will be discussed.
3.
Melanoma vaccines Kazuhito
Hayashibe,
Yutaka Mishima
and Soldano
Ferrone
Department of Dermatology, Kobe University School of Medicine, Kobe
A large number of patients have been injected with various tumor vaccines including novel immunological adjuvants, anti-idiotype MoAbs and carbohydrate antigens over the recent fifty years. However all of them have been of limited success to obtain substantial responses against melanoma except a few occasional cases. To develop new reagents with a firmer immunological basis, our approach is to screen an expression cDNA library constructed with a cultured human melanoma cell line mRNA utilizing sera from patients with melanoma. A cloned cDNA (1029 bps), designated as D-l, encodes a polypeptide with the apparent molecular weight of
40 kd. The size of the melanoma-associated antigen polypeptide D- 1 is different from that of previously described melanoma-associated antigens defined with antibodies from patients with melanoma and with mouse MoAbs. The nucleic acid sequence of cDNA D-l has no striking homology with previously reported sequences of mammalian genes. In situ hybridization on surgically removed melanoma tissues has indicated that this antigen is expressed in vivo. Thus D-l melanoma-associated antigen may be a useful immunogen to implement active specific immunotherapy in patients with melanoma.